Skip to main content

Table 5 PFS in patient subgroups

From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Category Patient Subgroup
Age, years <  65 years ≥ 65 years
 N 53 35
 Patients who progressed or died, n (%) 42 (79) 28 (80)
 Median PFS, months (95% CI) 16.6 (12.5–26.8) 20.1 (12.7–23.9)
Brain metastases at screening Yes No
 N 27 61
 Patients who progressed or died, n (%) 23 (85) 47 (77)
 Median PFS, months (95% CI) 14.0 (11.0–22.1) 19.2 (12.8–28.0)
EGFR mutation typea Common Uncommon
 N 72 16
 Patients who progressed or died, n (%) 56 (78) 14 (88)
 Median PFS months, (95% CI) 19.2 (14.2–23.9) 9.0 (5.5–20.2)
Afatinib line of therapy First-line Second-line
 N 66 22
 Patients who progressed or died, n (%) 50 (76) 20 (91)
 Median PFS, months (95% CI) 20.2 (14.2–27.0) 12.9 (7.2–26.7)
Patients with an afatinib dose reductionb No Yes
 N 54 34
 Patients who progressed or died, n (%) 41 (76) 29 (85)
 Median PFS, months (95% CI) 20.2 (13.6–31.3) 14.2 (11.7–22.1)
  1. CI confidence interval, EGFR epidermal growth factor receptor, PFS progression-free survival
  2. aCommon mutations indicates patients whose tumors harbor EGFR exon 19 deletions only or L858R substitutions only: uncommon mutations indicates patients whose tumors harbor EGFR mutation categories other than exon 19 deletions only and L858R only; bDose reduction within the first 6 months of treatment